Correspondence | Published:

Balancing open source stem cell science with commercialization

Nature Biotechnology volume 29, pages 115116 (2011) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Technol. Anal. Strategic Management 19, 257–277 (2007).

  2. 2.

    , & Technol. Anal. Strategic Management 18, 1–17 (2006).

  3. 3.

    , , & Br. Med. J. 326, 1159–1160 (2003).

  4. 4.

    European Commission. Off. J. Eur. Union L324, 121–137 (2007).

  5. 5.

    US Food and Drug Administration. Code of Federal Regulations. Good Tissue Practice for Blood and Biologics Companies. Title 21, Vol. 8. (21 CFR 1271) (FDA, Washington, DC, USA, 1 April 2009). <>

  6. 6.

    & Nat. Biotechnol. 25, 419–424 (2007).

  7. 7.

    Anonymous. Nature 460, 933 (2009).

Download references

Acknowledgements

Funding from the UK Economic and Social Research Council for the Innogen Centre (G.L. and J.T.) is acknowledged.

Author information

Affiliations

  1. Roslin Cells Ltd., Roslin, Midlothian, UK.

    • Aidan Courtney
    •  & Paul de Sousa
  2. School of Law, University of Edinburgh, Edinburgh, UK.

    • Carol George
    •  & Graeme Laurie
  3. Innogen Centre, University of Edinburgh, Edinburgh, UK.

    • Joyce Tait

Authors

  1. Search for Aidan Courtney in:

  2. Search for Paul de Sousa in:

  3. Search for Carol George in:

  4. Search for Graeme Laurie in:

  5. Search for Joyce Tait in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Joyce Tait.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.1773

Further reading Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing